BioXcel Therapeutics, Inc. (BTAI) Bundle
An Overview of BioXcel Therapeutics, Inc. (BTAI)
General Summary of BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological and immuno-oncology disorders. Founded in 2017, the company leverages artificial intelligence to identify and advance promising drug candidates.
Key Products and Services
- IGALMI™ (dexmedetomidine sublingual film) - FDA-approved for acute agitation in schizophrenia and bipolar disorder patients
- BXCL501 - AI-discovered treatment for agitation associated with neurological and psychiatric conditions
- BXCL701 - Immuno-oncology therapy targeting advanced prostate cancer
Financial Performance (2023 Q4)
| Financial Metric | Amount |
|---|---|
| Total Revenue | $36.4 million |
| Net Loss | $54.2 million |
| Cash and Equivalents | $188.3 million |
Market Position
BioXcel Therapeutics is recognized as an emerging leader in AI-driven drug discovery and development, with a focus on innovative neurological and oncology treatments.
Research and Development
- 4 active clinical-stage programs
- Over 15 ongoing clinical trials
- AI platform enabling rapid drug candidate identification
Stock Performance
| Stock Metric | Value |
|---|---|
| Ticker Symbol | BTAI |
| Average Trading Volume | 387,000 shares |
| 52-Week Price Range | $5.12 - $22.37 |
Mission Statement of BioXcel Therapeutics, Inc. (BTAI)
Mission Statement of BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI) mission statement focuses on innovative pharmaceutical development, specifically in neuroscience and immuno-oncology therapeutic areas.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Pharmaceutical Innovation | Advanced AI-driven drug development | 2 clinical-stage product candidates as of 2024 |
| Neuroscience Solutions | Developing transformative treatments | IGALMI™ (dexmedetomidine) sublingual film approved for acute agitation |
| Immuno-Oncology Research | Targeted cancer therapeutic approaches | BTAI-1806 clinical development stage |
Strategic Research Priorities
- AI-enhanced drug discovery platform
- Precision medicine development
- Neuroscience and oncology therapeutic focus
Research Investment
Research and development expenses: $54.3 million for fiscal year 2023
Product Pipeline Metrics
| Product | Therapeutic Area | Development Stage |
|---|---|---|
| IGALMI™ | Acute Agitation | FDA Approved |
| BTAI-1806 | Immuno-Oncology | Clinical Trial Phase |
Technological Approach
AI-driven drug discovery platform utilizing proprietary computational technologies
Financial Performance Indicators
Total revenue for 2023: $18.2 million
Cash and cash equivalents as of December 31, 2023: $146.7 million
Vision Statement of BioXcel Therapeutics, Inc. (BTAI)
Vision Statement of BioXcel Therapeutics, Inc. (BTAI)
Innovative Precision Medicine Approach
BioXcel Therapeutics focuses on developing advanced AI-powered precision medicine solutions in neuroscience and immuno-oncology domains. As of Q4 2023, the company's research and development pipeline demonstrates commitment to transformative therapeutic innovations.
| R&D Focus Area | Current Pipeline Status | Development Stage |
|---|---|---|
| Neuroscience | BXCL501 | Phase III Clinical Trials |
| Immuno-Oncology | BXCL701 | Phase II Clinical Trials |
Strategic Technology Integration
BioXcel leverages artificial intelligence for drug discovery and development processes. Key technological capabilities include:
- Machine learning algorithms for drug candidate identification
- Advanced predictive modeling in clinical research
- AI-enhanced patient stratification techniques
Financial Performance Indicators
| Financial Metric | 2023 Value |
|---|---|
| Research & Development Expenses | $54.3 million |
| Cash and Cash Equivalents | $132.5 million |
Clinical Development Strategy
Precision Medicine Approach: Focused on developing targeted therapies with potential for higher efficacy and reduced side effects.
- Neuroscience therapeutic areas: Agitation, depression
- Immuno-oncology focus: Prostate cancer, other solid tumors
Core Values of BioXcel Therapeutics, Inc. (BTAI)
Core Values of BioXcel Therapeutics, Inc. (BTAI) in 2024
Innovation and Scientific Excellence
BioXcel Therapeutics demonstrates commitment to innovation through its research and development efforts.
| R&D Investment | Amount |
|---|---|
| 2023 R&D Expenses | $67.4 million |
| Percentage of Revenue Invested in R&D | 87.3% |
Patient-Centric Approach
BioXcel focuses on developing transformative therapies for patients with neurological and immuno-oncological disorders.
- IGALMI™ (dexmedetomidine) sublingual film for agitation
- BXCL501 for acute treatment of agitation
- BXCL701 in immuno-oncology
Ethical Conduct and Transparency
| Compliance Metric | 2024 Status |
|---|---|
| Clinical Trial Transparency | 100% registered on ClinicalTrials.gov |
| Regulatory Compliance Audits | Zero major non-compliance findings |
Collaborative Research Ecosystem
Strategic partnerships and collaborations drive BioXcel's research capabilities.
- Partnership with Yale University
- Collaboration with Memorial Sloan Kettering Cancer Center
- Research agreements with multiple pharmaceutical research institutions
Commitment to Shareholder Value
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $24.6 million |
| Cash and Cash Equivalents | $186.4 million |
| Market Capitalization | Approximately $350 million |
BioXcel Therapeutics, Inc. (BTAI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.